合并使用ACEI/ARB与接受阿比特龙治疗的前列腺癌患者生存的关联:两项随机试验的事后分析
本研究基于COU-AA-301和COU-AA-302两项随机试验的事后观察性分析,评估合并使用ACEI/ARB与接受阿比特龙治疗的前列腺癌患者生存结局的关联。结果显示,ACEI/ARB单药治疗及含ACEI/ARB的多药降压方案均与更长的影像学无进展生存期(rPFS)、总生存期(OS)和前列腺癌特异性生存期(PCSS)相关,多变量分析结果一致。
要点
- ACEI/ARB单药与AA组更长的rPFS、OS和PCSS相关。
- 含ACEI/ARB的多药降压方案亦与更长的rPFS、OS和PCSS相关。
- 多变量分析显示ACEI/ARB与改善的rPFS、OS和PCSS独立相关。
核心结论
- 在接受阿比特龙治疗的前列腺癌患者中,合并使用ACEI/ARB与更长的rPFS、OS和PCSS相关。
- 含ACEI/ARB的降压方案在这些患者中的潜在作用值得进一步研究。
研究设计与样本
- 基于COU-AA-301和COU-AA-302两项随机试验的事后观察性分析。
- 采用Kaplan-Meier法评估rPFS、OS和PCSS,Cox比例风险模型计算HR及95%CI。
主要发现
- ACEI/ARB单药治疗与更长的rPFS(HR 0.82, 95%CI 0.59-1.13; HR 0.71, 95%CI 0.53-0.95)、OS(HR 0.66, 95%CI 0.41-1.06; HR 0.70, 95%CI 0.53-0.92)和PCSS(HR 0.72, 95%CI 0.44-1.19; HR 0.67, 95%CI 0.49-0.92)相关。
- 含ACEI/ARB的多药降压方案与更长的rPFS(HR 0.74, 95%CI 0.59-0.92; HR 0.71, 95%CI 0.54-0.94)、OS(HR 0.76, 95%CI 0.57-1.01; HR 0.72, 95%CI 0.55-0.94)和PCSS(HR 0.71, 95%CI 0.51-0.99; HR 0.62, 95%CI 0.46-0.83)相关。
- 多变量分析显示ACEI/ARB与改善的rPFS(HR 0.72, 95%CI 0.60-0.86; HR 0.75, 95%CI 0.60-0.94)、OS(HR 0.71, 95%CI 0.56-0.91; HR 0.70, 95%CI 0.56-0.88)和PCSS(HR 0.73, 95%CI 0.55-0.96; HR 0.64, 95%CI 0.50-0.82)相关。
临床怎么用
- 对于接受阿比特龙治疗且合并高血压的前列腺癌患者,选择含ACEI/ARB的降压方案可能与更好的生存结局相关。
- 该发现来自事后分析,尚不能作为改变临床实践的确定性证据,需前瞻性研究验证。
局限性
- 本研究为事后观察性分析,存在固有偏倚可能。
- ACEI/ARB单药治疗的部分生存关联95%CI跨越1,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in prostate cancer (PCa) patients. The management of CVD, including hypertension, holds equal significance to cancer treatment. However, the optimal antihypertensive agent for blood pressure management in PCa patients receiving abiraterone acetate (AA) is still unclear. This study aims to investigate the association between various antihypertensive regimens and survival outcomes in PCa patients treated with AA. METHODS: We performed a post-hoc observational analysis using data from COU-AA-301 and COU-AA-302. Radiographic progression-free survival (rPFS), overall survival (OS) and prostate cancer-specific survival (PCSS) were evaluated using the Kaplan-Meier method. Cox proportional hazards models were used to obtain hazard ratios (HRs) and associated 95% confidence intervals (CIs). RESULTS: Among the AA groups of COU-AA-301 and COU-AA-302, angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) monotherapy was associated with longer rPFS (HR 0.82, 95% CI 0.59-1.13; HR 0.71, 95% CI 0.53-0.95), OS (HR 0.66, 95% CI 0.41-1.06; HR 0.70, 95% CI 0.53-0.92) and PCSS (HR 0.72, 95% CI 0.44-1.19; HR 0.67, 95% CI 0.49-0.92). Multiple-class antihypertensive treatment regimens including ACEI/ARBs were associated with longer rPFS (HR 0.74, 95% CI 0.59-0.92; HR 0.71, 95% CI 0.54-0.94), OS (HR 0.76, 95% CI 0.57-1.01; HR 0.72, 95% CI 0.55-0.94) and PCSS (HR 0.71, 95% CI 0.51-0.99; HR 0.62, 95% CI 0.46-0.83). Multivariable analysis indicated that ACEI/ARBs were associated with improved rPFS (HR 0.72, 95% CI 0.60-0.86; HR 0.75, 95% CI 0.60-0.94), OS (HR 0.71, 95% CI 0.56-0.91; HR 0.70, 95% CI 0.56-0.88) and PCSS (HR 0.73, 95% CI 0.55-0.96; HR 0.64, 95% CI 0.50-0.82). CONCLUSIONS: In this post-hoc analysis, concomitant use of ACEI/ARBs was associated with longer rPFS, OS and PCSS in PCa patients treated with AA. The potential role of ACEI/ARB-containing antihypertensive regimens in these patients warrants further investigation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00638690, NCT00887198.
引用
- Zhao J, Cai X, Mo Z, et al. Association between concomitant ACEI/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials. Prostate Cancer Prostatic Dis. 2026. PMID: 42286315. doi:10.1038/s41391-026-01128-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。